Last reviewed · How we verify
TP-38
At a glance
| Generic name | TP-38 |
|---|---|
| Also known as | immunotoxin |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors (PHASE2)
- Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors (PHASE2)
- TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP-38 CI brief — competitive landscape report
- TP-38 updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI